Health and Fitness Health and Fitness
Thu, December 1, 2011
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011

Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference


//health-fitness.news-articles.net/content/2011/ .. annual-piper-jaffray-health-care-conference.html
Published in Health and Fitness on Wednesday, November 23rd 2011 at 4:06 GMT by Market Wire   Print publication without navigation


Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care... -- CARLSBAD, Calif., Nov. 23, 2011 /PRNewswire/ --

Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference

[ ]

CARLSBAD, Calif., Nov. 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at Piper Jaffray's Health Care Conferenceon Wednesday, November 30, 2011 at 8:00 a.m. ET at the New York Palace.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ]. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources